Drug Trial Radar · NCT07049328
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 16, 2025
Primary completion
Jul 16, 2027
Study completion Dec 15, 2027
Sponsor
- Lead sponsor
- HCW BiologicsIndustry
- Sponsor type
- Industry
- First posted
- Jul 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
Conditions
- Alopecia Areata(AA)
Interventions
HCW9302, an IL-2 fusion proteinDrug
Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs) in Subjects Receiving HCW9302 MonotherapyTime frame: 9 Weeks
- Designate the recommended Phase 2 dose level (RP2D) for Phase 2 study of HCW9302 in subjects with AATime frame: 9 Weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
James A. Haley Veterans' Hospital
Tampa, Florida · Recruiting
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.